Catalent Acquires MaSTherCell Global

05:14 EST 14 Feb 2020 | CHEManager

US contract development and manufacturing organization Catalent has acquired MaSTherCell Global for $315 million cash, boosting its cell and gene therapy capabilities. The New Jersey-based company financed the purchase with the proceeds of an underwritten public offering of its common stock, which completed in early February.

Original Article: Catalent Acquires MaSTherCell Global


More From BioPortfolio on "Catalent Acquires MaSTherCell Global"

Quick Search

Relevant Topic

Gene Therapy
Gene therapy is the use of DNA as a pharmaceutical agent to treat disease. It derives its name from the idea that DNA can be used to supplement or alter genes within an individual's cells as a therapy to treat disease. The most common form of gene th...